Registrational study of pegcetacoplan in intermediate dry age-related macular degeneration
Latest Information Update: 17 Aug 2021
At a glance
- Drugs Pegcetacoplan (Primary)
- Indications Dry age-related macular degeneration
- Focus Registrational; Therapeutic Use
- Sponsors Apellis Pharmaceuticals
- 17 Aug 2021 New trial record
- 09 Aug 2021 According to an Apellis Pharmaceuticals media release, company plans to initiate this registrational study of pegcetacoplan in intermediate dry age-related macular degeneration (AMD) in 2022, if the DERBY and OAKS studies meet their primary efficacy endpoint in the monthly arm.